TAP Pharmaceutical Products has agreed to a co-promotion agreementwith Novartis Pharmaceuticals Corporation for Famvir (famciclovir), an oralantiviral prescription medication. Under the terms of the agreement, TAP will be responsible for promoting Famvir to the obstetrician/gynecology (OB/GYN) medical community. Financial terms of the agreement were not disclosed.